These data are of translational relevance as increased pulmonary vascular endothelialitis, thrombosis, and angiogenesis are observed in COVID-19 patients.15,16 In addition, atorvastatin reduces the expression of ANGPT2, which emerges as a biomarker of endothelial activation in COVID-19 and predicts COVID-19 patients to be admitted to ICU.17 Analysis of protein expression revealed that atorvastatin treatment leads to increased protein expression of KLF2 and eNOS, while decreases the expression of VCAM1 (Fig. 4c). The gene discussed is KLF2; the disease is COVID-19.